MedPath

Zenith Alpha™ Abdominal Endovascular Graft

Completed
Conditions
Aorto-iliac Aneurysm
Abdominal Aortic
Registration Number
NCT03061825
Lead Sponsor
Cook Research Incorporated
Brief Summary

The purpose of this study is to evaluate the clinical performance of the Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • A patient is considered eligible for inclusion in the study if the patient has an infrarenal abdominal aortic or aorto-iliac aneurysm and is intended to be treated with the Zenith Alpha™ Abdominal Endovascular Graft
Exclusion Criteria
  • Life expectancy less than (<) 2 years
  • Inability or refusal to give informed consent by the patient or legally authorized representative
  • Unwilling or unable to comply with the study follow-up

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Device Success2 years

Technical success (successful introduction and deployment of the device in the absence of surgical conversion or mortality) plus freedom from the following: abdominal aneurysm rupture, conversion, Type I or III endoleak, graft limb occlusion and abdominal aneurysm size increase \> 5 mm.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (5)

London Health Sciences Center

🇨🇦

London, Ontario, Canada

Hamilton General Hospital

🇨🇦

Hamilton, Ontario, Canada

Toronto General Hospital

🇨🇦

Toronto, Ontario, Canada

Nova Soctia Health Authority

🇨🇦

Halifax, Nova Scotia, Canada

Vancouver Hospital and Health Science Center

🇨🇦

Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath